Vaccine used	Trial	Population	Outcome measure	Results
Encepur	Bock 1990	56 healthy males aged 20 to 50 years	Geometric means of TBE antibody titres 28 days after second inoculation (as assayed by ELISA, haemagglutination inhibition test, and neutralization test): minimum, median, and maximum values	1 µg dose of vaccine required to induce > 90% seroconversion after 2 doses
Encepur	Harabacz 1992	279 healthy adults aged 18 to 69 years	Seroconversion at days 0, 28, 42, 56, 300, 314, and 328 (conventional schedule), and at days 0, 21, 28, 35, 49, and 321 (abbreviated schedule); seroconversion defined as 8 in haemagglutination inhibition test, 2 in neutralization test, and 160 in ELISA	"No major differences were detected between three dosage between 1 and 2 mcg either in immunogenicity or in respect of reactogenicity"
FSME‐IMMUN (new)	Ehrlich 2003	405 healthy adults aged 16 to 65 years	Seroconversion, defined as ELISA value, was < 63 VIEU/mL before study entry and at least 126 VIEU/mL after respective vaccination, or if the neutralization test 100 value was > 10	After 2nd dose (ELISA) 1.2 vs 0.6 μg: RR 1.13 (1.05 to 1.22) 2.4 vs 0.6 μg: RR 1.14 (1.06 to 1.23) After 3rd dose (ELISA) 1.2 vs 0.6 μg: RR 1.03 (0.99 to 1.07) 2.4 vs 0.6 μg: RR 1.04 (1.01 to 1.08)
TicoVac	Eder 2003i	298 toddlers, aged 6 months to 3 years	Seroconversion defined as a positive ELISA result of at least 126 VIEU/mL or 4‐fold titre increase	2.57 vs 1.29 μg 2nd dose: RR 1.13 (0.99 to 1.28) 3.29 vs 1.65 μg 3rd dose: all reached seroconversion
TicoVac	Eder 2003ii	261 children aged 4 to 12 years	Seroconversion defined as a positive ELISA result of at least 126 VIEU/mL or 4‐fold titre increase	3.29 vs 1.65 μg 2nd dose: RR 1.06 (1.01 to 1.10) 3.29 vs 1.65 μg 3rd dose: all reached seroconversion